Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q4 2014 · 10-K
Revenue$31.24M$31.24M+202.3% vs Q4 2013 Net Income$3.79M$3.79MN/M vs Q4 2013 EPS Diluted$0.09$0.09N/M vs Q4 2013 Operating Incomederived$5,124,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Operating Cash Flowderived$6,263,000N/M Free Cash Flowderived$6,145,000N/M Margins · derivedOperating margin16.4%+126.3 pt vs Q4 2013
Net margin12.1%+228.9 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 12, 2015 · 71 d after period end